Safety, tolerance, biodistribution, and MR imaging enhancement of the liver with gadobenate dimeglumine: Results of clinical pharmacologic and pilot imaging studies in nonpatient and patient volunteers

Academic Radiology

Volumn 6, Issue 5, 1999, Pages 282-291

  Spinazzi, A ^a   Lorusso, V ^a   Pirovano, G ^a   Kirchin, M ^a  

^a Bracco SpA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GADOBENATE DIMEGLUMINE; PLACEBO;

ADULT; AGED; CLINICAL TRIAL; CONFERENCE PAPER; CONTRAST ENHANCEMENT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG EXCRETION; DRUG FECES LEVEL; DRUG SAFETY; DRUG TOLERABILITY; DRUG URINE LEVEL; FEMALE; HEADACHE; HUMAN; HUMAN EXPERIMENT; LIVER DISEASE; LIVER PARENCHYMA; MAJOR CLINICAL STUDY; MALE; MUSCLE SPASM; MYALGIA; NAUSEA; NORMAL HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PILOT STUDY; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; TREMOR; VOMITING; XEROSTOMIA;

EID: 0033277563     PISSN: 10766332     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1076-6332(99)80451-6     Document Type: Conference Paper

References (28)

1. Detection of liver neoplasms: Techniques and outcomes
2. Abdominal imaging
3. Contrast-enhanced MR imaging
4. Contrast-enhanced MR imaging of the liver
5. Liver metastases: Improved detection with dynamic gadolinium-enhanced MR imaging?
6. Use of contract agents in the detection and differentiation of focal liver lesions by MR imaging: Gd-DTPA, Mn-DPDP, and iron oxide
7. Hepatic hemangiomas: A multi-institutional study of appearance of T2-weighted and serial gadolinium-enhanced gradient-echo MR images
8. Hepatic metastases and cavernous hemangiomas: Distinction with standard- and triple-dose gadoteridol-enhanced MR imaging
9. Primary MR liver neoplasms: Imaging with pathologic correlation
10. Focal liver lesions: Characterization with nonenhanced and dynamic contrast material-enhanced MR imaging
11. Peripheral washout: A sign of malignancy on dynamic gadolinium-enhanced MR images of focal liver lesions
12. 3DFT-FISP MRI with gadopentetate dimeglumine in differential diagnosis of small liver tumors
13. Hepatic transport of gadobenate dimeglumine in TR- rats
14. Evaluation of the hepatocyte-specific contrast agent gadobenate dimeglumine for MR imaging of acute hepatitis in a rat model
15. Binding of gadobenate dimeglumine to proteins extravasated into interstitial space enhances conspicuity of reperfused infarcts
16. Soluble-type hepatobiliary contract agents fob MR imaging
17. Gd-BOPTA/ Dimeg: Experimental disease imaging
18. Hepatobiliary contrast agents for magnetic resonance imaging
19. Gd-BOPTA/Dimeg: A new hepatobiliary contrast agent for magnetic resonance imaging
20. High-performance liquid chromatographic assay of the magnetic resonance imaging contrast agent gadobenate in plasma, urine, and bile
21. Analytical methods validation: Bioavailability, bioequivalence, and pharmacokinetic studies
22. Pharmacokinetics and tolerance of Gd-BOPTA/Dimeg (0.25 M) in healthy volunteers
23. Tolerance and pharmacokinetics evaluation of Gd-BOPTA/Dimeg (0.5 M) at high doses in healthy volunteers
24. Liver III: Gadolinium-based hepatobiliary contrast agents (Gd-EOB-DTPA and Gd-BOPTA/Dimeg)
25. Interim results of phase II clinical testing of gadobenate dimeglumine
26. Pharmacokinetics of Gd-DTPA/ dimeglumine after intravenous injection into healthy volunteers
27. Pharmacokinetic behavior of gadoteidol injection